Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.

ABSTRACT:

Background

So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of "The Cancer Genome Atlas (TCGA)" database.

Methods

One hundred two FDA-approved targeted cancer drugs were compiled and molecular targets defined. Drugs were considered as potentially effective if targeted genes showed (1) an increase in copy number, (2) gain of function with oncogene activation, (3) specific alterations responsive to approved drugs. Additionally, genetic changes that confer drug resistance and/or sensitivity were evaluated.

Results

Fifty percentage of patients with GC may be treatable with non-GC but FDA-

SUBMITTER: Hescheler DA 

PROVIDER: S-EPMC7305081 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature